990P Updated results of a phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)

Authors :: U. Mueller
K. Nakajima
T. Ishida
Anthony B. El-Khoueiry
Roniel Cabrera
Max Sung
Dirk Waldschmidt
William P. Harris
Richard D. Kim
Peter R. Galle
Source :: Annals of Oncology. 31:S691-S692
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Hematology
Pembrolizumab
medicine.disease
First line treatment
chemistry.chemical_compound
chemistry
Regorafenib
Internal medicine
Hepatocellular carcinoma
Medicine
business

Full Text Access

Tools